Joint Working Agreements

The development and implementation of a micro site to serve as a repository of information for all Care Home managers and teams - to enable best practice and support compliance with the National Harm Free Care programme across Norfolk


'Harm free' care is the national roll out of the pilot Safety Express QIPP programme that was implemented by the national QIPP Safe Care work stream. It helps NHS teams in their aim to eliminate harm in patients from four common conditions:

  • pressure ulcers
  • falls
  • urinary tract infections in patients with a catheter
  • new venous thromboembolism (VTE)

These conditions affect over 200,000 people each year in England alone, leading to avoidable suffering and additional treatment for patients and a cost to the NHS of more than £400million. The 'harm free' care programme supports NHS to eliminate these four harms through one plan within and across organisations. This builds on existing improvement work and can be implemented at local level and integrated with existing routines. It helps organisations to consider complications from the patient's perspective, with the aim of every patient being 'harm free' as they move through the system. Takeda UK is engaging with Norfolk Community Health and Care NHS Trust in a Joint Working programme to support the embedding of the principles of 'harm free' care in all safety improvement programmes by supporting the development of a 'prevention of fall' microsite resource for frontline staff, as part of the existing 'harm free' care e-learning modules. The microsite is in line with the 'Falls in older People Pathway' (NICE 2013) and will be able to be utilised in nursing homes and the NHS community. The Joint Working Programme will be of seven months duration.

Patient benefits: Reductions in fall and consequent Hospital admissions. Enhance care based on prevention principles.

NHS benefits: Reduction of Hospital admissions and assosciated reductions in NHS cost. Effective on line management tools for falls prevention.

Takeda benefits: Improved corporate reputation amongst local, regional and national stakeholders. Nice is recommending assessment of osteoporosis risk as part of the 'Falls in older People Pathway' risk assessment criteria which as a result may result in increased prescription of osteoporosis prevention medicines as part of this programme and therefore pharmaceutical companies may benefit from an increase in the number of prescriptions in this patient group.

Pilot study to develop CKD services in primary care to meet NICE quality standards


Takeda UK Ltd  worked with City Hospitals Sunderland on a pilot study under a new Joint Working Agreement to evaluate the level of current identification and treatment of CKD 3 patients. Recent studies indicated that there was a significant gap in meeting CKD quality standards in primary care both in terms of identifying patients with CKD 3 and treating to NICE targets. This Joint Working project aimed to validate this assumption in a practice in Sunderland CCG, using remote MIQUEST queries. These data were used to support CKD and anaemia patients across Sunderland. Takeda and City Hospitals Sunderland expected the project to improve patient access to effective treatment closer to home, as well as promote a better understanding of and involvement with their condition. Takeda benefited from the better identification and treatment of patients with iron deficient CKD, as well as form the development of a cost effective IV iron service to support the QIPP agenda. As well as more patients being optimally treated, the study helped City Hospitals Sunderland meet NICE Quality Standards of Care for CKD and develop plans to meet the outcomes framework and CCG commissioning plan. The Joint Working Project ran from 2 January 2013 for three months.

Patient safety in diabetes, renal and cardiovascular disease - development and use of an interactive on-line resource tool


This project was carried out in partnership with the Institute of Diabetes for Older People (IDOP) at Bedfordshire and Hertfordshire Postgraduate Medical School. The aim of the Joint Working Agreement was to produce an on-line educational and training tool and DVD for NHS health professionals to enhance patient safety in the areas of diabetes, renal and cardiovascular disease. A series of 3 regional interactive meetings/seminars with NHS professionals were organised to roll out the programme. It was intended that the Joint Working Project would benefit patients with cardiovascular disease, renal disease and/or diabetes by them being better cared for by health professionals who have benefited from up-to-date training and education in patient safety. In line with the mission of IDOP it was hoped that the project will increase the Institute's reputation and credibility in the area of patient safety. Takeda benefited through a better understanding of the needs of both patients and the NHS in the area of patient safety. Both parties had committed resource in support of this Joint Working project which ran from 18 November 2011 to 31 October 2012.

Development and management of an integrated heart failure screening project in Principia Partners in Health


In partnership with Principia Partners in Health the project aimed to screen primary care databases and registers for patients at risk of heart failure, ensure these had been validated by echocardiogram and patients' treatment were optimised and managed within the shared care protocol. The anticipated benefits for patients were ensuring that 'at risk' patients had better access to recommended treatment and services. Principia had a greater and more efficient use of currently commissioned community heart failure nurses which in turn improved QOF measures and reduced hospital admissions. Takeda benefited through a better understanding of the needs of both patients and the NHS in this area and also through the increased inappropriate use of heart failure medication. Principia Partners in Health & Takeda UK Limited had both committed resource in support of this Joint Working project which ran from 4th November 2011 to 30th April 2012.

Targeting patients at high risk of hypertension and diabetes


In partnership with NHS Westminster the project aimed to demonstrate to Commissioners via QIPP (Quality, Innovation, Prevention & Productivity) that a health check targeting patients at high risk of hypertension and diabetes via community pharmacies using social marketing was the most effective process of finding patients undiagnosed with these conditions. Since the project was a first of its kind, it was intended that when the project was completed that it would be written up and published for shared learning and best practice purposes for example published on the website of the National Social Marketing Centre (NSMC). This project was intended as a proof of concept in NHS Westminster, which has already commissioning health checks in Community Pharmacy.


                                                                                                                                                                                                                               Date of Preparation: March 2016


Takeda Pharma